Clinical Trial Update: Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial comparing pralatrexate to erlotinib in previously treated non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Pralatrexate (pralatrexate)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-01-20